Margins matter. The more Numerex (Nasdaq: NMRX ) keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders. Healthy margins often separate pretenders from the best stocks in the market. That's why we check up on margins at least once a quarter in this series. I'm looking for the absolute numbers, so I can compare them to current and potential competitors, and any trend that may tell me how strong Numerex's competitive position could be.
Here's the current margin snapshot for Numerex over the trailing 12 months: Gross margin is 42.4%, while operating margin is 4.4% and net margin is 9.9%.
Unfortunately, a look at the most recent numbers doesn't tell us much about where Numerex has been, or where it's going. A company with rising gross and operating margins often fuels its growth by increasing demand for its products. If it sells more units while keeping costs in check, its profitability increases. Conversely, a company with gross margins that inch downward over time is often losing out to competition, and possibly engaging in a race to the bottom on prices. If it can't make up for this problem by cutting costs -- and most companies can't -- then both the business and its shares face a decidedly bleak outlook.
10 Best Gas Utility Stocks To Buy For 2015: Kansas City Southern (KSU)
Kansas City Southern, through its subsidiaries, engages primarily in the freight rail transportation business. It operates north/south rail between Kansas City, Missouri, and various ports along the Gulf of Mexico in Alabama, Louisiana, Mississippi, and Texas in the midwest and southeast regions of the United States. The company also operates direct rail passageway between Mexico City and Laredo in Texas, serving various Mexico?s industrial cities and 3 of its shipping ports; and a 157-mile rail line extending from Laredo, Texas to the port city of Corpus Christi, Texas, as well as owns the northern half of the rail bridge at Laredo, Texas. In addition, Kansas City Southern holds a concession to operate a 47-mile railroad located adjacent to the Panama Canal, as well as operates and promotes commuter and tourist passenger services. Further, the company operates a bulk materials handling facility with deep-water access to the Gulf of Mexico at Port Arthur, Texas that stores and transfers petroleum coke from rail cars to ships primarily for export; and a railroad wood tie treatment facility. It serves customers conducting business in various industries, including electric-generating utilities, chemical and petroleum products, industrial and consumer products, agriculture and mineral products, automotive products, and intermodal freight transportation. The company was formerly known as Kansas City Southern Industries, Inc. and changed its name to Kansas City Southern in 2002. Kansas City Southern was founded in 1962 and is based in Kansas City, Missouri.
Advisors' Opinion:- [By Ben Levisohn]
Investors have created a monster of their own–the emerging markets, an amalgamation of various countries that have very little in common–and like the monster in the original Frankenstein, they’re coming for their creator. The iShares MSCI Emerging Markets ETF (EEM) fell 3.9% to $38.24 this week–dragging down U.S. stocks with it. The S&P 500 fell 2.6% to 1,790.29, its largest one-week decline since June, 2012, as it was pulled lower by International Game Technology (IGT) and Kansas City Southern (KSU). The Dow Jones Industrial Average fell 3.5% to 15,879.11, its largest decline since November, 2011, with�EI Du Pont De Nemours (DD) and�General Electric (GE) the biggest losers. The 10-year Treasury yield fell to 2.726%, down from 3.006% at the start of 2014, as investors flocked to the relative safety of bonds.
Top 10 Healthcare Technology Stocks To Watch For 2014: StealthGas Inc.(GASS)
StealthGas Inc., a ship-owning company, through its subsidiaries, provides international seaborne transportation services worldwide. The company transports petroleum gas products in liquefied form, including propane, butane, butadiene, isopropane, propylene, and vinyl chloride monomer. It also transports refined petroleum products, such as gasoline, diesel, crude oil, fuel oil, jet fuel, edible oils, and chemicals. As of January 9, 2012, the company had a fleet of 33 liquefied petroleum gas (LPG) carriers with a total capacity of 153,088 cubic meters, 3 medium range product tankers, and 1 Aframax oil tanker. It serves LPG producers comprising national and independent energy companies, energy traders, and industrial users. StealthGas Inc. was founded in 2004 and is headquartered in Athens, Greece.
Advisors' Opinion:- [By Tim Melvin]
Several shipping stocks have already started to move higher this year, but in a fashion that will be typical of the volatility in the sector, we saw an opportunity created this week. StealthGas (GASS) reported earnings that fell well short of analyst expectations, and the stock plummeted by almost 8 percent for the week.
- [By Eric Volkman]
StealthGas (NASDAQ: GASS ) has ambitions to raise $100 million from the capital markets. The company put a price tag on its upcoming public share flotation, and upped the volume in the process -- 10 million shares are to be sold, as opposed to the originally planned 8 million, and they will be priced at $10.00 apiece.
- [By Sally Jones]
StealthGas Inc. (GASS) - Yield 0.00%
StealthGas Inc. is up 38% over 12 months. The current share price is around $9.40, down 11% since John Keeley made a new buy as of June 30, 2013.
Top 10 Healthcare Technology Stocks To Watch For 2014: Energy Select Sector SPDR Fund (XLE)
Energy Select Sector SPDR Fund (the Fund) seeks to provide investment results that correspond to the price and yield performance of the Energy Select Sector of the S&P 500 Index (the Index). The Index includes companies that primarily develop and produce crude oil and natural gas, and provide drilling and other energy-related services.
The Fund utilizes a passive or indexing investment approach to invest in a portfolio of stocks that seek to replicate the Index. The Fund�� investment advisor is SSgA Funds Management, Inc.
Advisors' Opinion:- [By Ben Levisohn]
Shares of Continental Resources have gained 4.8% to $55.47 at 1:28 p.m., easily topping the 1.4% rise in the Energy Select Sector SPDR ETF (XLE), as oil prices have gained 1.4% to $78.97.
- [By Stephen Leeb]
The bellwether S&P Energy Select Sector (XLE), has done very well so far this year, keeping pace with the overall market's push upwards; XLE remains a buy.
Top 10 Healthcare Technology Stocks To Watch For 2014: ResMed Inc (RMD)
ResMed Inc., (ResMed), incorporated on March 31, 1994, is a holding company for the ResMed Group. The Company, through its subsidiaries, is a developer, manufacturer and distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. Sleep-disordered breathing (SDB) includes obstructive sleep apnea (OSA), and other respiratory disorders that occur during sleep. The Company has developed a number of products for SDB and other respiratory disorders including airflow generators, diagnostic products, mask systems, headgear and other accessories. Its manufacturing operations are located in Australia, Singapore, France, Germany, Malaysia and the United States. Its distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, Norway and Sweden. In December 2013, ResMed Inc acquired Unimedis SRO, a surgical appliance and manufacturing company.
Air Flow Generators
The Company produces continuous positive airway pressure (CPAP), variable positive airway pressure (VPAP) and AutoSet systems for the titration and treatment of SDB. The flow generator systems deliver positive airway pressure through a patient interface, either a small nasal mask, nasal pillows system, or full-face mask. Its VPAP units deliver bilevel therapy. There are two preset pressures: a higher pressure as the patient breathes in, and a lower pressure as the patient breathes out. AutoSet systems are based on a technology to monitor breathing and can also be used in the diagnosis, treatment and management of OSA. The Company�� Stellar 100 and 150 ventilation devices, provide both invasive and non invasive ventilation applications for adult and pediatric patients.
ResMed Inc.�� CPAP products include S8 Escape, S9 Elite and S9 Escape. Its VPAP products include VPAP III STA with QuickNav, VPAP S / VPAP IV, VPAP IV ST, S8 Auto 25, VPAP Tx Lab System, S9 VPAP S, S9 VPAP ST! , S9 VPAP Auto, S9 VPAP Adapt, S9 AutoSet CS, S9 Auto 25 and S9 VPAP COPD. The Company�� automatic positive airway pressure products include S9 AutoSet and S9 Escape Auto. Its ventilation products include Elisee 150, VS III and Stellar 100 and 150.
Masks, Accessories, Motors and Diagnostic Products
Masks, accessories, motors and diagnostic products together accounted for approximately 46% of its net revenues in fiscal 2012. Its Mask products include Activa LT, Swift LT for Her, Swift FX, Mirage SoftGel, Quattro FX, Swift FX for Her, Mirage FX, Mirage FX for Her, Pixi Pediatric Mask, Quattro FX for Her, Swift FX Bella, Quattro Air and Swift FX Nano. Its diagnostic products includes ApneaLink + Oximetry and ApneaLink Plus (U.S.)
Accessories and Other Products
The Company to assist those professionals diagnosing or managing the treatment of patients have data communications and control products, such as the EasyCare, ResLink, ResControl, ResControl II, TxControl, ResScan and ResTraxx modules that facilitate the transfer of data and other information to and from the flow generators. These products include humidifiers, such as H5i and H4i, which connect directly with the CPAP, VPAP and AutoSet flow generators to humidify and heat the air delivered to the patient, helping to prevent the drying of nasal passages that can cause discomfort. Other optional accessories include cold passover humidifiers, carry bags and breathing circuits. The Company�� data/patient management products include S9 Embletta Adapter, ResScan v3.14, ResTraxx v17.1., ResTraxx v18.3, ResScan v3.16 and EasyCare 1.0.
The Company competes with Philips BV, DeVilbiss Healthcare., Fisher & Paykel Healthcare Corporation Limited, Apex Medical Corp, BMC Medical Co. Ltd and Weinmann Gerate fur Medizin GmbH + Co. KG.
Advisors' Opinion:- [By Sean Williams]
ResMed (NYSE: RMD ) : 2% projected forward yield
Like the previous companies, ResMed has operations on a global scale, but unlike the preceding device makers, its focus is on medical equipment that helps diagnose and treat sleeping disorders. Whereas growth at Smith & Nephew and Medtronic has been slow-and-go in recent quarters, ResMed has seen sales take off. In its recently reported fourth-quarter results, ResMed delivered record quarterly revenue and income of $414.6 million and $86.2 million. Revenue in its Americas and combined Europe/Asia Pacific regions rose by 11% and 12%, respectively, with the company announcing a 47% increase to its quarterly dividend.� - [By STOCKPICKR]
Medical equipment maker ResMed (RMD) is another name that's starting to look "toppy" after a bullish start to the year. RMD has more or less kept pace with the S&P 500 in 2014, climbing just over 11% from January to today -- but shares started forming a long-term triple-top over the summer, and that setup is getting close to completion this fall.
It's worth noting that long-term price setups come with equally long term trading implications when they trigger.
The triple-top that RMD is showing is a fairly rare pattern, but the trigger is pretty perfunctory: if shares break down below support at $48, then sellers are in control, and it's time to unload them. Downside isn't a foregone conclusion in ResMed, but this setup only gets invalidated if shares can close above their prior highs at $54.
Top 10 Healthcare Technology Stocks To Watch For 2014: Harmonic Inc.(HLIT)
Harmonic Inc. designs, manufactures, and sells video infrastructure products and system solutions to create, prepare, and deliver a range of video services for television and media platforms in the united States and internationally. Its products include video production platforms and playout solutions, such as video servers used by broadcasters, content owners, and multi-channel network operators to create and play-to-air television channels; video-optimized storage, which provides storage capacity and access bandwidth to support media production applications comprising video editing, content transformation, and media library management; and media applications that provide media integrated management and workflow control over content stored on its systems. The company offers video processing products, including broadcast encoders; contribution and distribution encoders; stream processing and statistical multiplexing solutions; content preparation and delivery for multi-scr een applications; decoders and descramblers; and management and control software. It also provides edge products that integrate routing, multiplexing, scrambling, and modulation into a single package; optical transmitters and amplifiers, which operates at various optical wavelengths and serves long-haul and local transport applications in the cable distribution network; optical nodes to supports network architectures for bandwidth delivered to a service area; and return path transmitters that support two-way transmission capabilities for analog or digital transport. In addition, the company offers technical support and professional services, such as maintenance and support; and consulting, implementation, and integration services. Harmonic Inc. sells its products through direct sales force, independent distributors, and integrators to cable, satellite and telco, and broadcast and media companies. The company was founded in 1988 and is headquartered in San Jose, California. Advisors' Opinion:
- [By Seth Jayson]
Harmonic (Nasdaq: HLIT ) is expected to report Q1 earnings on April 23. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Harmonic's revenues will decrease -10.8% and EPS will decrease -66.7%. - [By Roberto Pedone]
Harmonic (HLIT) designs, manufactures and sells versatile and hig-performance video products and system solutions that enable service providers to efficiently deliver the next generation of broadcast and on-demand services. This stock closed up 1.8% to $7.81 in Tuesday's trading session.
Tuesday's Range: $7.61-$7.85
52-Week Range: $3.96-$8.04
Tuesday's Volume: 656,000
Three-Month Average Volume: 777,544From a technical perspective, HLIT bounced modestly higher here right above its 50-day moving average of $7.51 with decent upside volume. This stock has been uptrending a bit for the last month, with shares moving higher from its low of $7.10 to its intraday high of $7.85. During that move, shares of HLIT have been consistently making higher lows and higher highs, which is bullish technical price action. That move is now pushing shares of HLIT within range of triggering a big breakout trade. That trade will hit if HLIT manages to take out some near-term overhead resistance at $8 to its 52-week high at $8.04 with high volume.
Traders should now look for long-biased trades in HLIT as long as it's trending above its 50-day at $7.51 or above more support at $7, and then once it sustains a move or close above those breakout levels with volume that hits near or above 777,544 shares. If that breakout triggers soon, then HLIT will set up to enter new 52-week high territory, which is bullish technical price action. Some possible upside targets off that move are $9.50 to $10.50.
- [By Lee Jackson]
Harmonic Inc. (NASDAQ: HLIT) is a top small cap name to buy at Oppenheimer. Revenue in the second quarter totaled $117.1 million, and bookings were $126.3 million. Non-GAAP net income was $5.6 million, or $0.05 per share. That bottom-line result is a welcome improvement compared to the adjusted net loss of $0.02 per share a year ago. The stock was up as much as 16% after earnings, and it may be a top name to own for the rest of the year. The consensus price target for the stock is $7.
- [By Eddie Staley]
Shares of Harmonic (NASDAQ: HLIT) were down 13.46 percent to $6.18 after the company lowered its Q2 forecast and issued a weak Q3 guidance.
Riverbed Technology (NASDAQ: RVBD) shares tumbled 6.77 percent to $18.97 after the company lowered its Q2 revenue forecast.
Top 10 Healthcare Technology Stocks To Watch For 2014: Ashley(l)
Laura Ashley Holdings plc, together with its subsidiaries, engages in the design, manufacture, sourcing, distribution, sale, and licensing of clothing, accessories, and home furnishings in the United Kingdom and internationally. It offers various furniture products, including beds, upholstered furniture, mirrors, and cabinet furniture; home accessories, such as lighting products, gifts, bed linen, rugs, throws, cushions, and children?s accessories; and decorative products comprising curtains, blinds, fabrics, paints, decorative accessories, and wall coverings. The company also offers fashion products, such as clothing that include dresses, knitwear, tops, blouses, skirts, trousers, leggings, coats, jackets, swimwear, and shoes, as well as accessories comprising bags, purses, jewellery, and scarves. In addition, it provides design services for homes; and licenses various products, such as stationery, wooden flooring, blinds, interior window shutters, carpets, nursery produ cts, fireplaces, garden products, eyewear, tiles, promotional gifting, toiletries, shoes, and Fairtrade clothing. The company sells its products through retail stores, online, and mail order. As of January 29, 2011, it operated 217 stores, including 138 mixed product stores, 55 home stores, 22 home concession stores, 1 gifts and accessories store, and 1 clearance outlet in the United Kingdom; and 240 franchised stores in 29 countries. The company is based in London, the United Kingdom.
Advisors' Opinion:- [By Paul Ausick]
Big Earnings Movers: Petroleo Brasileiro SA (NYSE: PBR) is up 9.1% at $17.35 after reporting earnings and getting a ratings boost. Merck & Co. Inc. (NYSE: MRK) is down 2.5% at $45.39 as the company struggles to boost revenues. Burger King Worldwide Inc. (NYSE: BKW) is up 5.8% at $20.91 as franchise revenues rose much faster than costs. Loews Corp. (NYSE: L) is down 0.2% at $48.70.
- [By Julius Ferraro]
Diamond offshore is a $9 billion dollar offshore driller that is currently 50.4% owned by Loews Corporation (L). I like that the Tisch family has a significant ownership because in the case of an economic downturn, Diamond Offshore can be provided with the capital that it may need by some of Loews other businesses. Its Expected to earn $4.80 for this year and trades at a fair valuation of 11.8 times earnings. In addition, out of all of the offshore drillers Diamond is the most conservative with $1.2 billion in cash and $1.5 billion in debt. Diamond Offshore is the only A rated drilling contractor.
Top 10 Healthcare Technology Stocks To Watch For 2014: Galectin Therapeutics Inc (GALT)
Galectin Therapeutics Inc., formerly Pro-Pharmaceuticals, Inc., incorporated on January 26, 2001, is a development-stage company. The Company is engaged in drug development to create therapies for cancer and fibrotic disease. As of December 31, 2011, the Company has two compounds in development, one is to be used in cancer therapy and the other intended to be used in the treatment of liver fibrosis and fatty liver disease. These two compounds are produced from different natural starting materials, both possessing the property, which lends itself to binding to and inhibiting galectin proteins. GM-CT-01, the Company's product candidate for cancer therapy, is a linear polysaccharide polymer consisted of mannose and galactose that has a defined chemical structure and is derived from a plant source. GR-MD-02, the Company's product for treatment of liver fibrosis and fatty liver disease with inflammation and fibrosis, is a polysaccharide polymer possessing both linear and globular structures, which also is derived from a plant source.
GM-CT-01 has in development for the therapy of colorectal cancer and is in a Phase I/II clinical trial as a combination therapy with a tumor vaccine in patients with advanced melanoma. Based on the completed Phase I and partially completed Phase II clinical trials, the Company is exploring two additional potential indicia for the use of GM-CT-01 in combination with cancer chemotherapy. There are two additional pathways for the development of GM-CT-01 for use in treatment of cancer. GM-CT-01 was found to be generally safe when studied in a Phase I clinical trial in end-stage cancer patients with multiple tumor types alone and in combination with 5-Fluorouracil (5-FU), which is an Food and Drug Administration (FDA)-approved chemotherapy used for treatment of various types of cancer.
Advisors' Opinion:- [By Roberto Pedone]
Galectin Therapeutics (GALT) offers drug research and development to create new therapies for fibrotic disease and cancer. This stock closed up 9.6% to $12.06 in Monday's trading session.
Monday's Volume: 674,000
Three-Month Average Volume: 222,171
Volume % Change: 149%Shares of GALT jumped higher on Monday after Ascendiant initiated coverage on the stock with a buy recommendation.
From a technical perspective, GALT spiked sharply higher here with strong upside volume. This stock has been uptrending for the last three months, with shares ripping higher from its low of $3.95 to its recent high of $13.21. During that move, shares of GALT have been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of GALT within range of triggering a near-term breakout trade. That trade will hit if GALT manages to take out Monday's high of $12.44 and then once it clears its 52-week high at $13.21 with high volume.
Traders should now look for long-biased trades in GALT as long as it's trending above some near-term support levels at $11 or at $10 and then once it sustains a move or close above those breakout levels with volume that hits near or above 222,171 shares. If that breakout hits soon, then GALT will set up to enter new 52-week-high territory above $13.21, which is bullish technical price action. Some possible upside targets off that breakout are $15 to $16.
No comments:
Post a Comment